US EditionNovo Nordisk's Wegovy Tied To Increased Risk Of Rare Vision-Loss Disorder, European Regulators Say - Novo Nordisk (NYSE:NVO)
- The safety committee of the European Medicines Agency has completed its evaluation of semaglutide-containing medications and determined that these drugs may very rarely be linked to the development of the eye disorder NAION in some patients.
- The review began in December after evidence showed that semaglutide, a medication for diabetes and weight management, is associated with approximately twice the chance of experiencing NAION relative to individuals not using the drug.
- This eye condition, which can lead to sudden, painless loss of vision, is considered very rare but has been reported in up to one person per 10,000 using semaglutide-containing medications such as Wegovy, Ozempic, and Rybelsus.
- Data from a 350,000-patient study showed long-term semaglutide use more than doubled NAION risk, and the EMA advised updating product information accordingly.
- The EMA's decision implies patients should monitor vision changes and that labeling changes will spread across the EU to inform users of this rare risk.
30 Articles
30 Articles
Secondary effects may affect up to 1 in 10,000 people taking these medicines. The European Medicines Agency recommends that the poultry be updated.
EU Health Watch Dog Warns Weight Loss Drug May Cause Sudden Blindness
The European Medicines Agency (EMA) has warned that popular weight loss drugs may lead to sudden blindness. The health watchdog concluded that semaglutide-based medications – including Ozempic, Wegovy, and Rybelsus – increase the risk of [...] The post EU Health Watch Dog Warns Weight Loss Drug May Cause Sudden Blindness appeared first on The People's Voice.
A European committee has assessed that the eye disease Naion is a rare side effect of the use of semaglutide.
Medications can increase the risk of developing eye disease that can cause vision loss.
MedPage Today
Anti-Aging, Acupuncture and Health NewsGLP-1 Drug Can Cause Rare, Potentially Blinding Side Effect, EMA Warns
(MedPage Today) -- A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. Following a review of all available data, the...
Coverage Details
Bias Distribution
- 50% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
